
Supplementary Material*

Rosenblum HG, Lewis RM, Gargano JW, et al. Human papillomavirus vaccine impact and effectiveness through 12 years after vaccine introduction in the United States, 2003 to 2018. Ann Intern Med. 17 May 2022. [Epub ahead of print]. doi:10.7326/M21-3798

- Supplement Figure 1: Participation and sample collection among females, National Health and Nutrition Examination Survey, 2003–2018
- Supplement Figure 2: Participation and sample collection among males, National Health and Nutrition Examination Survey, 2011–2018
- Supplement Table 1: Characteristics of sexually experienced males aged 14–24 years, overall and by HPV vaccination history, 2013–2016
- Supplement Table 2: Human papillomavirus (HPV) prevalence and prevalence ratios, sexually experienced males aged 14–24 years overall and by vaccination history, 2013–2016

* This supplementary material was provided by the authors to give readers further details on their article. The material was not copyedited.

Supplement Figure 1: Participation and sample collection among females, National Health and Nutrition Examination Survey, 2003–2018



Information about sexual experience history available for 1986 females 2003–2006, 1248 for 2007–2010, 1370 for 2011–2014 and 1191 in 2015–2018


^{*}The response rate during 2003–2004 and 2005–2006 was 80.0% and 80.9% for the interview portion and 76.0% and 77.8% for the examination portion, respectively

[†]The response rate during 2007–2008 and 2009–2010 among females 78.6% and 79.7% for the interview portion and 75.5% and 77.4% for the examination portion, respectively

[±]The response rate during 2011–2012 and 2013–214 among females was 72.6% and 71.4% for the interview portion and 69.4% and 68.8% for the examination portion, respectively

[§]The response rate during 2015–2016 and 2017–2018 among females was 62.6 % and 53.5% for the interview portion and 60.0% and 50.5% for the examination portion, respectively

Supplement Figure 2: Participation and sample collection among males, National Health and Nutrition Examination Survey, 2011–2018



^{*}The response rate during 2011–2012 and 2013–2014 among males was 72.7% and 70.6% for the interview portion and 69.6% and 68.1% for the examination portion, respectively

[†]The response rate during 2015–2016 and 2017–2018 among males was 60.1% and 50.3% for the interview portion and 57.4% and 47.2% for the examination portion, respectively

[±]The response rate during 2013–2014 and 2015–2016 among males was 70.6% and 60.1% for the interview portion and 68.1% and 57.4% for the examination portion, respectively

[§]Information about sexual experience history available for 1402 males 2011–2014, 1196 for 2015–2018 and 1339 in 2013–2016

	% (95% CI)		
Characteristic	Overall	Vaccinated	Unvaccinated
	n= 661	n=124	n= 431
HPV vaccination history			
≥1 dose	22.1 (18.5-26.3)	-	-
Vaccination age <15*	-	30.4 (21.1-41.6)	-
≥3 lifetime sex partners	65.1 (60.7-69.3)	59.4 (49.7-68.4)	67.3 (60.7-73.3)
Race ethnicity			
Non-Hispanic White	53.6 (46.2-60.8)	59.8 (47.0-71.3)	52.6 (45.3-59.7)
Non-Hispanic Black	15.6 (12.1-19.9)	14.5 (8.8-22.9)	16.2 (12.1-21.4)
Mexican American	14.4 (10.6-19.3)	11.7 (7.0-19.1)	14.2 (10.1-19.6)
Other races	16.3 (12.7-20.7)	14.0 (8.4-22.4)	17.0 (12.8-22.1)
Below poverty	22.7 (18.0-28.2)	17.7 (10.2-29.0)	25.4 (20.3-31.4)

^{*}Among those vaccinated; refers to age at first dose

HPV = Human papillomavirus; CI = confidence interval

Note: All estimates are weighted using NHANES examination weights

Supplement Table 2: Human papillomavirus (HPV) prevalence and prevalence ratios, sexually experienced males aged 14–24 years overall and by vaccination history, 2013–2016

HPV types and vaccination history	Prevalence, % (95% CI)	Prevalence ratio (95% CI)	
4vHPV [*]			
Overall	3.0 (1.8-4.9)	-	
Vaccinated	$1.8 \ (0.4-6.8)^{\$}$	0.49 (0.11-2.20)	
Unvaccinated	3.5 (1.9-6.4)	Ref	
Non-4vHPV †			
Overall	33.7 (29.7-37.9)	-	
Vaccinated	30.7 (21.5-41.8)	0.89 (0.58-1.37)	
Unvaccinated	34.3 (29.1-40.0)	Ref	
HPV31, 33, 45			
Overall	3.1 (1.9-5.0)	-	
Vaccinated	6.0 (1.5-21.0) [§]	2.16 (0.37-12.50)	
Unvaccinated	$2.8~(1.4-5.5)^{\pm}$	Ref	

[§]Relative standard error >50%

Reference

HPV = Human papillomavirus; CI = confidence interval

We use HPV nomenclature to be consistent with our past publications, however, nomenclature has evolved since the Roche product was launched. IS39 is a subtype of HPV82, HPV55 was reclassified as HPV44, and HPV64 was reclassified as HPV34

Note: All estimates are weighted using NHANES examination weights

^{*4}vHPV= quadrivalent HPV vaccine types, HPV6,11,16,18

[†]Non-4vHPV: 33 types detected using Linear Array that are not HPV6,11,16, or 18

[±]Relative standard error 30-50%